B-MS and AZ report dapagliflozin results

Phase IIb results published in the journal Diabetes Care showed that Bristol-Myers Squibb and AstraZeneca's SGLT2 inhibitor dapagliflozin  reduced glycemia and body weight in treatment-naive type 2 diabetes  patients.

The prospective, randomized, double-blind, placebo-controlled,  parallel-group study involved 389 treatment-naive adults . The  respective US and Anglo-Swedish drug majors are co-developing the  candidate.

After 12 weeks, individuals receiving dapagliflozin demonstrated a  significant adjusted mean decrease in HbA1c from baseline of -0.71% for  dapagliflozin 2.5mg, -0.72% for 5mg, -0.85% for 10mg, -0.55% for 20mg  and -0.90% for 50mg, vs -0.18% for placebo (p<0.001; except 20mg,  p=0.007). No log-linear dose response relationship was demonstrated  (p=0.41).